KR20100082349A - 치환된 ｎ－페닐-비피롤리딘 우레아 및 이의 치료적 용도 - Google Patents
치환된 ｎ－페닐-비피롤리딘 우레아 및 이의 치료적 용도 Download PDFInfo
- Publication number
- KR20100082349A KR20100082349A KR1020107010481A KR20107010481A KR20100082349A KR 20100082349 A KR20100082349 A KR 20100082349A KR 1020107010481 A KR1020107010481 A KR 1020107010481A KR 20107010481 A KR20107010481 A KR 20107010481A KR 20100082349 A KR20100082349 A KR 20100082349A
- Authority
- KR
- South Korea
- Prior art keywords
- methyl
- phenyl
- bipyrrolidinyl
- carboxylic acid
- urea
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 0 Cc(c(*)c(cc1)N(CC2)CC2N2C(*)CCC2)c1N(*)C(N(C)*)=O Chemical compound Cc(c(*)c(cc1)N(CC2)CC2N2C(*)CCC2)c1N(*)C(N(C)*)=O 0.000 description 2
- CTQMYZRBBXTDJI-UHFFFAOYSA-N CC(CCC1)N1C(CC1)CN1c(cc1)cc(C)c1NC(NC1CCCCC1)=O Chemical compound CC(CCC1)N1C(CC1)CN1c(cc1)cc(C)c1NC(NC1CCCCC1)=O CTQMYZRBBXTDJI-UHFFFAOYSA-N 0.000 description 1
- JEMKFSIFMPGUKZ-UHFFFAOYSA-N CC(CCC1)N1C(CC1)CN1c(cc1)ccc1NC(Nc1cccc(C#N)c1)=O Chemical compound CC(CCC1)N1C(CC1)CN1c(cc1)ccc1NC(Nc1cccc(C#N)c1)=O JEMKFSIFMPGUKZ-UHFFFAOYSA-N 0.000 description 1
- MHZFBPFOIBNKBF-YDNXMHBPSA-N C[C@@H](CCC1)N1C(CC1)CN1c(cc1)cc(C)c1NC(NCC1CCCCC1)=O Chemical compound C[C@@H](CCC1)N1C(CC1)CN1c(cc1)cc(C)c1NC(NCC1CCCCC1)=O MHZFBPFOIBNKBF-YDNXMHBPSA-N 0.000 description 1
- KHAUVQIIEQSBGB-RKDXNWHRSA-N C[C@H](CCC1)N1[C@H]1CNCC1 Chemical compound C[C@H](CCC1)N1[C@H]1CNCC1 KHAUVQIIEQSBGB-RKDXNWHRSA-N 0.000 description 1
- MISMLRVNMAZYSK-LGKIWNRFSA-N C[C@H](CCC1)[C@H]1C(CC1)CN1c(cc1)cc(C)c1N Chemical compound C[C@H](CCC1)[C@H]1C(CC1)CN1c(cc1)cc(C)c1N MISMLRVNMAZYSK-LGKIWNRFSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Anesthesiology (AREA)
- Transplantation (AREA)
- Toxicology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98060607P | 2007-10-17 | 2007-10-17 | |
| US60/980,606 | 2007-10-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20100082349A true KR20100082349A (ko) | 2010-07-16 |
Family
ID=40248052
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020107010481A Ceased KR20100082349A (ko) | 2007-10-17 | 2008-10-14 | 치환된 ｎ－페닐-비피롤리딘 우레아 및 이의 치료적 용도 |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US8222290B2 (enExample) |
| EP (1) | EP2215058B1 (enExample) |
| JP (1) | JP5380455B2 (enExample) |
| KR (1) | KR20100082349A (enExample) |
| CN (1) | CN101903341B (enExample) |
| AT (1) | ATE534625T1 (enExample) |
| AU (1) | AU2008312641A1 (enExample) |
| CA (1) | CA2702933C (enExample) |
| CY (1) | CY1112391T1 (enExample) |
| DK (1) | DK2215058T3 (enExample) |
| ES (1) | ES2378011T3 (enExample) |
| HR (1) | HRP20120166T1 (enExample) |
| IL (1) | IL205002A0 (enExample) |
| MA (1) | MA31889B1 (enExample) |
| MX (1) | MX2010003948A (enExample) |
| MY (1) | MY148807A (enExample) |
| NZ (1) | NZ584692A (enExample) |
| PL (1) | PL2215058T3 (enExample) |
| PT (1) | PT2215058E (enExample) |
| RS (1) | RS52221B (enExample) |
| RU (1) | RU2478094C2 (enExample) |
| SI (1) | SI2215058T1 (enExample) |
| WO (1) | WO2009052068A1 (enExample) |
| ZA (1) | ZA201002114B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2212283T3 (pl) | 2007-10-17 | 2012-01-31 | Sanofi Sa | Podstawione karboksyamidy N-fenylobipirolidyny i ich zastosowanie terapeutyczne |
| CN101903339B (zh) * | 2007-10-17 | 2012-06-27 | 赛诺菲-安万特 | 取代的n-苯基-联吡咯烷羧酰胺及其治疗用途 |
| MX2010004003A (es) | 2007-10-17 | 2010-04-30 | Sanofi Aventis | N-fenil-pirrolidinilmetlipirrolidin amidas sustituidas y uso terapeutico de las mismas. |
| KR20090129927A (ko) | 2008-06-13 | 2009-12-17 | 주식회사 엘지화학 | 발열체 및 이의 제조방법 |
| US9611171B2 (en) | 2008-06-13 | 2017-04-04 | Lg Chem, Ltd. | Heating element and manufacturing method thereof |
| US10412788B2 (en) | 2008-06-13 | 2019-09-10 | Lg Chem, Ltd. | Heating element and manufacturing method thereof |
| JP5833105B2 (ja) | 2010-05-11 | 2015-12-16 | サノフイ | 置換ｎ−ヘテロアリールスピロラクタムビピロリジン類、その製造及び治療的使用 |
| JP2013526530A (ja) * | 2010-05-11 | 2013-06-24 | サノフイ | 置換されたｎ−フェニルスピロラクタムビピロリジン、その製造及び治療上の使用 |
| WO2011143162A1 (en) * | 2010-05-11 | 2011-11-17 | Sanofi | Substituted n-heteroaryl bipyrrolidine carboxamides, preparation and therapeutic use thereof |
| TW201206910A (en) * | 2010-05-11 | 2012-02-16 | Sanofi Aventis | Substituted N-heterocycloalkyl bipyrrolidinylphenyl amide derivatives, preparation and therapeutic use thereof |
| TW201206939A (en) | 2010-05-11 | 2012-02-16 | Sanofi Aventis | Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof |
| AR081034A1 (es) | 2010-05-11 | 2012-05-30 | Sanofi Aventis | Derivados de n-heteroaril tetrahidro-isoquinolina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades del sistema nervioso central |
| JP5766278B2 (ja) | 2010-05-11 | 2015-08-19 | サノフイ | 置換されたｎ−アルキルおよびｎ−アシルテトラヒドロ−イソキノリン誘導体、それらの製造および治療上の使用 |
| PE20140913A1 (es) | 2010-11-15 | 2014-08-22 | Abbvie Inc | Inhibidores de nampt y rock |
| HRP20151003T1 (hr) * | 2011-02-23 | 2015-10-23 | Suven Life Sciences Limited | Novi spojevi kao ligandi receptora histamina h3 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20020507A1 (es) * | 2000-10-17 | 2002-06-25 | Schering Corp | Compuestos no-imidazoles como antagonistas del receptor histamina h3 |
| WO2004037257A1 (en) * | 2002-10-23 | 2004-05-06 | Janssen Pharmaceutica, N.V. | Phenylpiperidines and phenylpyrrolidines as histamine h3 receptor modulators |
| US7223788B2 (en) * | 2003-02-14 | 2007-05-29 | Sanofi-Aventis Deutschland Gmbh | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments |
| DE10306250A1 (de) * | 2003-02-14 | 2004-09-09 | Aventis Pharma Deutschland Gmbh | Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| JP5052497B2 (ja) | 2005-03-17 | 2012-10-17 | イーライ リリー アンド カンパニー | ヒスタミンｈ３受容体アンタゴニストとしてのピロリジン誘導体 |
| BRPI0608653A2 (pt) * | 2005-04-01 | 2010-11-30 | Lilly Co Eli | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto ou um sal do mesmo |
| ES2370518T3 (es) * | 2005-07-01 | 2011-12-19 | Eli Lilly And Company | Agentes receptores h3 de histamina, preparación y usos terapéuticos. |
| US7943605B2 (en) * | 2005-10-27 | 2011-05-17 | Ucb Pharma S.A. | Compounds comprising a lactam or a lactam derivative moiety, processes for making them, and their uses |
| CN101903339B (zh) | 2007-10-17 | 2012-06-27 | 赛诺菲-安万特 | 取代的n-苯基-联吡咯烷羧酰胺及其治疗用途 |
| PL2212283T3 (pl) | 2007-10-17 | 2012-01-31 | Sanofi Sa | Podstawione karboksyamidy N-fenylobipirolidyny i ich zastosowanie terapeutyczne |
| MX2010004003A (es) | 2007-10-17 | 2010-04-30 | Sanofi Aventis | N-fenil-pirrolidinilmetlipirrolidin amidas sustituidas y uso terapeutico de las mismas. |
-
2008
- 2008-10-14 CA CA2702933A patent/CA2702933C/en not_active Expired - Fee Related
- 2008-10-14 EP EP08838702A patent/EP2215058B1/en active Active
- 2008-10-14 HR HR20120166T patent/HRP20120166T1/hr unknown
- 2008-10-14 RS RS20120067A patent/RS52221B/sr unknown
- 2008-10-14 CN CN2008801212096A patent/CN101903341B/zh not_active Expired - Fee Related
- 2008-10-14 PT PT08838702T patent/PT2215058E/pt unknown
- 2008-10-14 AU AU2008312641A patent/AU2008312641A1/en not_active Abandoned
- 2008-10-14 WO PCT/US2008/079763 patent/WO2009052068A1/en not_active Ceased
- 2008-10-14 PL PL08838702T patent/PL2215058T3/pl unknown
- 2008-10-14 SI SI200830552T patent/SI2215058T1/sl unknown
- 2008-10-14 JP JP2010530054A patent/JP5380455B2/ja not_active Expired - Fee Related
- 2008-10-14 RU RU2010119554/04A patent/RU2478094C2/ru not_active IP Right Cessation
- 2008-10-14 ES ES08838702T patent/ES2378011T3/es active Active
- 2008-10-14 MY MYPI2010001300A patent/MY148807A/en unknown
- 2008-10-14 MX MX2010003948A patent/MX2010003948A/es active IP Right Grant
- 2008-10-14 KR KR1020107010481A patent/KR20100082349A/ko not_active Ceased
- 2008-10-14 AT AT08838702T patent/ATE534625T1/de active
- 2008-10-14 NZ NZ584692A patent/NZ584692A/en not_active IP Right Cessation
- 2008-10-14 DK DK08838702.2T patent/DK2215058T3/da active
-
2010
- 2010-03-15 US US12/724,045 patent/US8222290B2/en not_active Expired - Fee Related
- 2010-03-25 ZA ZA2010/02114A patent/ZA201002114B/en unknown
- 2010-04-11 IL IL205002A patent/IL205002A0/en unknown
- 2010-05-17 MA MA32842A patent/MA31889B1/fr unknown
-
2012
- 2012-02-23 CY CY20121100185T patent/CY1112391T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MY148807A (en) | 2013-05-31 |
| RU2010119554A (ru) | 2011-11-27 |
| HK1146056A1 (en) | 2011-05-13 |
| EP2215058A1 (en) | 2010-08-11 |
| AU2008312641A1 (en) | 2009-04-23 |
| CA2702933A1 (en) | 2009-04-23 |
| RU2478094C2 (ru) | 2013-03-27 |
| CN101903341A (zh) | 2010-12-01 |
| EP2215058B1 (en) | 2011-11-23 |
| ES2378011T3 (es) | 2012-04-04 |
| JP5380455B2 (ja) | 2014-01-08 |
| DK2215058T3 (da) | 2012-03-12 |
| IL205002A0 (en) | 2010-11-30 |
| CA2702933C (en) | 2012-12-18 |
| ATE534625T1 (de) | 2011-12-15 |
| MX2010003948A (es) | 2010-04-30 |
| MA31889B1 (fr) | 2010-12-01 |
| US8222290B2 (en) | 2012-07-17 |
| CN101903341B (zh) | 2012-10-03 |
| PT2215058E (pt) | 2012-03-06 |
| ZA201002114B (en) | 2010-12-29 |
| WO2009052068A1 (en) | 2009-04-23 |
| HRP20120166T1 (hr) | 2012-03-31 |
| CY1112391T1 (el) | 2015-12-09 |
| SI2215058T1 (sl) | 2012-03-30 |
| JP2011500697A (ja) | 2011-01-06 |
| RS52221B (sr) | 2012-10-31 |
| NZ584692A (en) | 2011-12-22 |
| US20100173908A1 (en) | 2010-07-08 |
| PL2215058T3 (pl) | 2012-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8222290B2 (en) | Substituted N-phenyl-bipyrrolidine ureas and therapeutic use thereof | |
| JP5377503B2 (ja) | 置換されたｎ−フェニル−ビピロリジンカルボキサミド及びその治療上の使用 | |
| US8618159B2 (en) | Substituted N-phenyl-bipyrrolidine carboxamides and therapeutic use thereof | |
| US8227504B2 (en) | Substituted N-phenyl-pyrrolidinylmethylpyrrolidine amides and therapeutic use thereof | |
| US8383814B2 (en) | Substituted tetrahydropyran spiro pyrrolidinone and piperidinone, preparation and therapeutic use thereof | |
| US8871788B2 (en) | Substituted N-alkyl and N-acyl tetrahydro-isoquinoline derivatives, preparation and therapeutic use thereof | |
| US8859588B2 (en) | Substituted N-heteroaryl bipyrrolidine carboxamides, preparation and therapeutic use thereof | |
| HK1146056B (en) | Substituted n-phenyl-bipyrrolidine ureas and therapeutic use thereof | |
| HK1146053B (en) | Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20100512 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20131011 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20150223 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20150521 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20150223 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |